GSK's Bosatria (mepolizumab) is a humanized mAb targeting IL-5, a
cytokine that regulates the activation of eosinophils. It was originally
developed for the treatment of hypereosinophilic syndrome, but GSK
withdrew its authorization application after the CHMP determined that
the data were insufficient to conclude whether there is a positive
benefit-risk balance for Bosatria in asthma (GSK, press release, July
29, 2009). GSK boasts multibillion dollar sales for its blockbuster,
Advair/Seretide, but Bosatria is not expected to reach this status,
since it will only be used in a limited number of refractory patients.

Scope

Overview of Asthma, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.

Detailed information on Bosatria including product description, safety
and efficacy profiles as well as a SWOT analysis.

Sales forecast for Bosatria for the top eight countries from 2013 to
2023.